Source: LexaGene
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • LexaGene (LXG) announced that its MiQLab System can perform the CDC monkeypox real-time PCR test
  • Should an emergency use authorization be declared for monkeypox, LexaGene’s management will take many factors into consideration when deciding whether to pursue action
  • Monkeypox is a viral disease with no known cure. Symptoms include fever, swollen lymph nodes, and a rash that forms blisters
  • Lexagene Holdings Inc. (LXG) is up 20.69 per cent, trading at C$0.175 per share at 11:20 am ET

LexaGene’s (LXG) MiQLab System can perform the Centers for Disease Control and Prevention (CDC) monkeypox real-time Polymerase Chain Reaction (PCR) test.

Dr. Jack Regan, Founder and CEO of LexaGene, commented on the news.

“During the COVID-19 pandemic, we advanced our company and our technology. The FDA has not yet declared an EUA for this epidemic, but should one be declared, LexaGene is in position to pursue such an authorization. The MiQLab System is a platform that can be quickly configured to detect any new pathogen and for this reason we continue to advance it as a solution for rapidly detecting newly emergent pathogens at the point-of-care.”

On July 23rd, the World Health Organization declared monkeypox a public health emergency of international concern, and on August 4th, the United States government declared the epidemic a public health emergency. 

The company noted that there is concern that back-to-school activities could result in a spike in infections.

Monkeypox is a viral disease with no known cure. Symptoms include fever, swollen lymph nodes, and a rash that forms blisters. Symptoms can be severe, particularly in children, pregnant women, and those who are immunocompromised. The disease can even be deadly on occasion.

LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry. 

Lexagene Holdings Inc. (LXG) is up 20.69 per cent, trading at C$0.175 per share at 11:20 am ET.


More From The Market Herald

" Revive Therapeutics (CSE:RVV) updates Bucillamine in treating COVID-19

Revive Therapeutics (RVV) announced an update of its Food and Drug Administration (FDA) phase three clinical trial for Bucillamine.
The Market Herald Video

" BioVaxys (CSE:BIOV) signs binding term sheet for distribution of Papilocare in the U.S.

BioVaxys Technology Corp. (BIOV) has signed a binding term sheet with Procare Health Iberia, S.L. of Barcelona, Spain.

" Satellos Bioscience (TSXV:MSCL) announces OTCQB listing

Common shares of Satellos Bioscience (MSCL) have commenced trading on the OTCQB Venture Market (OTCQB) under the symbol MSCLF.
Innocan Pharma - CEO Iris Bincovish

" Innocan Pharma (CSE:INNO) patent application for treatment of psoriasis of the scalp goes national

Innocan Pharma’s (INNO) patent application, which claims cannabinoid-based topical compositions can treat psoriasis of the scalp, has reached the national phase.